Compare AbCellera Biologics Inc (ABCL) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Capri Holdings Ltd — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Capri Holdings Ltd trades at $17.79 (market cap $2.23B). The key difference: AbCellera Biologics Inc and Capri Holdings Ltd are close in size by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| ABCL | CPRI | |
|---|---|---|
Market Cap | $2.35B | $2.23B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $27.66 |
52-Week Low | $2.78 | $16.79 |
Enterprise Value | $1.99B | $3.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
CPRI trades at $19.41, up 2.37% today, amid mixed signals with bearish technical indicators but improving fundamentals. Recent Q1 2026 earnings beat expectations with EPS of $0.22 versus $0.118, while revenue trends show stabilization after declines. The company's net income margin improved to 3.94% for 2026, though 2025 saw a significant loss. Analyst consensus is mixed with 44% buy ratings and a $23.43 price target, suggesting potential upside from current levels.
The outlook hinges on CPRI's turnaround execution, with risks including luxury demand volatility and high debt. Positive catalysts include projected FY2027 growth and cost management efforts. Investors should weigh the attractive P/S ratio of 0.65 against ongoing operational challenges and insider selling noted in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
